HIV-infected women susceptible to malnutrition during pregnancy, even with good antiretrovirol care

September 10, 2012 by Joyanna Hansen

Malnutrition is common among HIV-infected pregnant women even when they receive antiretroviral therapy, leading to low birth weight and other health problems in their infants, according to a recent study conducted by a Cornell University faculty member working with the Makerere University-UCSF Research Collaboration.

In one of the few studies that have looked at the nutritional status of pregnant, HIV-infected women receiving antiretroviral therapy, about 15 percent of the women lost weight over the course of their pregnancies. Almost half of the women were anemic, a condition often caused by iron deficiency, according to lead researcher Sera Young, a research scientist in Cornell's Division of .

"What we see is that even excellent clinical care on the best antiretroviral regimens that we have isn't sufficient for healthy pregnancies," said Young.

HIV is a "wasting disease," meaning that it depletes the body's muscle and fat stores. This combined with the increased nutritional needs of pregnancy make HIV-infected pregnant women particularly susceptible to malnutrition, Young said.

The researchers measured weight gain, iron status and other nutritional markers in 158 HIV-infected, pregnant Ugandan women receiving . The study also followed the women throughout their pregnancies and found that the also had poor ; about one-fifth of the babies had , and and stunting were common.

"There's no better predictor of a child's health than the mother's health," said Young. "Working to keep the moms healthy to be able to care for these little babies is a pretty compelling reason for this research."

One of the positive findings of the study is that no mother transmitted HIV in utero or while giving birth to the babies, said Young.

Young is spearheading an ongoing study looking at the effects of nutritional supplementation in HIV-infected pregnant women, with the hope that augmenting their diet during pregnancy will improve both maternal and infant health outcomes.

Diane Havlir and Deborah Cohan, both researchers at the University of California-San Francisco, were the primary investigators. The study was part of PROMOTE, a larger clinical trial investigating malaria outcomes in HIV-infected pregnant women receiving antiretroviral therapy.

The results of this study were published in the Aug. 7 issue of the journal PLoS One.

Explore further: Anti-HIV drug tenofovir is safe to take during pregnancy

Related Stories

Anti-HIV drug tenofovir is safe to take during pregnancy

May 15, 2012
Pre-birth exposure to the anti-HIV drug tenofovir does not adversely affect pregnancy outcomes and does not increase birth defects, growth abnormalities, or kidney problems in infants born to African women who are HIV positive, ...

Increased mortality in HIV-positive South African men versus women is unrelated to HIV/AIDS

September 4, 2012
In South Africa, HIV-infected men who are receiving treatment with anti-HIV drugs (antiretroviral therapy) are almost a third more likely to die than HIV-positive women who are receiving similar treatment: however, these ...

Drug combo much better than AZT alone at preventing mother-to-infant HIV transmission

June 20, 2012
Non-breastfed babies born to HIV-positive mothers who didn't receive antiretroviral therapy during pregnancy are routinely given zidovudine, commonly known as AZT, shortly after birth to prevent mother-to-child transmission ...

Recommended for you

Scientists find where HIV 'hides' to evade detection by the immune system

October 19, 2017
In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memory T-cells where infectious HIV 'hides' in the human ...

National roll-out of PrEP HIV prevention drug would be cost-effective

October 18, 2017
Providing pre-exposure prophylaxis (PrEP) medication to men who have sex with men who are at high risk of HIV infection (equivalent to less than 5% of men who have sex with men at any point in time) in England would be cost-effective, ...

Regulatory T cells harbor HIV/SIV virus during antiviral drug treatment

October 17, 2017
Scientists at Yerkes National Primate Research Center, Emory University have identified an additional part of the HIV reservoir, immune cells that survive and harbor the virus despite long-term treatment with antiviral drugs.

New research opens the door to 'functional cure' for HIV

October 17, 2017
In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively ...

Researchers create molecule that could 'kick and kill' HIV

October 5, 2017
Current anti-AIDS drugs are highly effective at making HIV undetectable and allowing people with the virus to live longer, healthier lives. The treatments, a class of medications called antiretroviral therapy, also greatly ...

A sixth of new HIV patients in Europe 50 or older: study

September 27, 2017
People aged 50 and older comprise a growing percentage of HIV patients in Europe, accounting for one in six new cases in 2015, researchers said Wednesday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.